Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis.

Wijnen BFM, Thielen FW, Konings S, Feenstra T, van der Gaag M, Veling W, de Haan L, Ising H, Hiligsmann M, Evers SMAA, Smit F, Lokkerbol J.

Expert Rev Pharmacoecon Outcomes Res. 2019 Jun 14. doi: 10.1080/14737167.2019.1632194. [Epub ahead of print]

PMID:
31195900
2.

Costs of people with diabetes in relation to average glucose control: an empirical approach controlling for year of onset cohorts.

Rodríguez-Sánchez B, Feenstra TL, Bilo HJG, Alessie RJM.

Eur J Health Econ. 2019 May 16. doi: 10.1007/s10198-019-01072-z. [Epub ahead of print]

PMID:
31098887
3.

A social cost-benefit analysis of two One Health interventions to prevent toxoplasmosis.

Suijkerbuijk AWM, Over EAB, Opsteegh M, Deng H, Gils PFV, Bonačić Marinović AA, Lambooij M, Polder JJ, Feenstra TL, Giessen JWBV, Wit GA, Mangen MJ.

PLoS One. 2019 May 10;14(5):e0216615. doi: 10.1371/journal.pone.0216615. eCollection 2019.

4.

Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.

Phi XA, Greuter MJW, Obdeijn IM, Oosterwijk JC, Feenstra TL, Houssami N, de Bock GH.

Breast. 2019 Jun;45:82-88. doi: 10.1016/j.breast.2019.03.004. Epub 2019 Mar 12.

PMID:
30904701
5.

Decision models of prediabetes populations: A systematic review.

Leal J, Morrow LM, Khurshid W, Pagano E, Feenstra T.

Diabetes Obes Metab. 2019 Jul;21(7):1558-1569. doi: 10.1111/dom.13684. Epub 2019 Apr 1.

PMID:
30828927
6.

Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia.

Wasir R, Irawati S, Makady A, Postma M, Goettsch W, Buskens E, Feenstra T.

PLoS One. 2019 Feb 19;14(2):e0212328. doi: 10.1371/journal.pone.0212328. eCollection 2019.

7.

Potential gains in health expectancy by improving lifestyle: an application for European regions.

Füssenich K, Nusselder WJ, Lhachimi SK, Boshuizen HC, Feenstra TF.

Popul Health Metr. 2019 Jan 17;17(1):1. doi: 10.1186/s12963-018-0181-5.

8.

Estimating disease prevalence from drug utilization data using the Random Forest algorithm.

Slobbe LCJ, Füssenich K, Wong A, Boshuizen HC, Nielen MMJ, Polder JJ, Feenstra TL, van Oers HAM.

Eur J Public Health. 2019 Jan 3. doi: 10.1093/eurpub/cky270. [Epub ahead of print]

PMID:
30608539
9.

The cost-utility of stepped-care algorithms according to depression guideline recommendations - Results of a state-transition model analysis.

Meeuwissen JAC, Feenstra TL, Smit F, Blankers M, Spijker J, Bockting CLH, van Balkom AJLM, Buskens E.

J Affect Disord. 2019 Jan 1;242:244-254. doi: 10.1016/j.jad.2018.08.024. Epub 2018 Aug 9.

PMID:
30216769
10.

Long-term incidence and risk factors of cardiovascular events in Asian populations: systematic review and meta-analysis of population-based cohort studies.

Irawati S, Wasir R, Floriaan Schmidt A, Islam A, Feenstra T, Buskens E, Wilffert B, Hak E.

Curr Med Res Opin. 2019 Feb;35(2):291-299. doi: 10.1080/03007995.2018.1491149. Epub 2018 Jul 30.

PMID:
29920124
11.

Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge.

Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, McEwan P, Leal J, Gray A, Foos V, Lamotte M, Feenstra T, O'Connor PJ, Brandle M, Smolen HJ, Gahn JC, Valentine WJ, Pollock RF, Breeze P, Brennan A, Pollard D, Ye W, Herman WH, Isaman DJ, Kuo S, Laiteerapong N, Tran-Duy A, Clarke PM.

Value Health. 2018 Jun;21(6):724-731. doi: 10.1016/j.jval.2018.02.002. Epub 2018 Apr 9.

12.

In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.

Hartmann R, Feenstra T, Valentino L, Dockal M, Scheiflinger F.

J Thromb Haemost. 2018 Jun 11. doi: 10.1111/jth.14203. [Epub ahead of print]

PMID:
29888855
13.

Corrigendum to "A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening" [Maturitas 109 (2018) 81-88].

Koleva-Kolarova RG, Daszczuk AM, de Jonge C, Abu Hantash MK, Zhan ZZ, Postema EJ, Feenstra TL, Pijnappel RM, Greuter MJW, de Bock GH.

Maturitas. 2018 Aug;114:73. doi: 10.1016/j.maturitas.2018.05.005. Epub 2018 May 17. No abstract available.

PMID:
29779854
14.

Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study.

Koleva-Kolarova RG, Greuter MJW, Feenstra TL, Vermeulen KM, de Vries EFJ, Parkin D, Buskens E, de Bock GH.

Oncotarget. 2018 Apr 13;9(28):19836-19846. doi: 10.18632/oncotarget.24869. eCollection 2018 Apr 13.

15.

Systematic review and meta-analysis of tube thoracostomy following traumatic chest injury; suction versus water seal.

Feenstra TM, Dickhoff C, Deunk J.

Eur J Trauma Emerg Surg. 2018 Dec;44(6):819-827. doi: 10.1007/s00068-018-0942-7. Epub 2018 Mar 15.

16.

A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening.

Koleva-Kolarova RG, Daszczuk AM, de Jonge C, Abu Hantash MK, Zhan ZZ, Postema EJ, Feenstra TL, Pijnappel RM, Greuter MJW, de Bock GH.

Maturitas. 2018 Mar;109:81-88. doi: 10.1016/j.maturitas.2017.12.009. Epub 2017 Dec 15. Erratum in: Maturitas. 2018 May 17;:.

PMID:
29452787
17.

Apathy Is Associated With Greater Decline in Subjective, but not in Objective Measures of Physical Functioning in Older People Without Dementia.

Henstra MJ, Feenstra TC, van der Velde N, van der Mast RC, Comijs H, Stek ML, Rhebergen D.

J Gerontol A Biol Sci Med Sci. 2019 Jan 16;74(2):254-260. doi: 10.1093/gerona/gly014.

PMID:
29415276
18.

Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources.

Hoogendoorn M, Feenstra TL, Boland M, Briggs AH, Borg S, Jansson SA, Risebrough NA, Slejko JF, Rutten-van Mölken MP.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 1;12:3183-3194. doi: 10.2147/COPD.S142378. eCollection 2017.

19.

The design of a Social Cost-Benefit Analysis of preventive interventions for toxoplasmosis: An example of the One Health approach.

Suijkerbuijk AWM, van Gils PF, Bonačić Marinović AA, Feenstra TL, Kortbeek LM, Mangen MJ, Opsteegh M, de Wit GA, van der Giessen JWB.

Zoonoses Public Health. 2018 Feb;65(1):185-194. doi: 10.1111/zph.12417. Epub 2017 Nov 12.

PMID:
29131528
20.

Computer simulation models of pre-diabetes populations: a systematic review protocol.

Leal J, Khurshid W, Pagano E, Feenstra T.

BMJ Open. 2017 Oct 5;7(10):e014954. doi: 10.1136/bmjopen-2016-014954.

21.

A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data.

Corro Ramos I, van Voorn GAK, Vemer P, Feenstra TL, Al MJ.

Value Health. 2017 Sep;20(8):1041-1047. doi: 10.1016/j.jval.2017.04.016. Epub 2017 May 29.

22.

Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research.

van Asselt T, Ramaekers B, Corro Ramos I, Joore M, Al M, Lesman-Leegte I, Postma M, Vemer P, Feenstra T.

Pharmacoeconomics. 2018 Jan;36(1):105-113. doi: 10.1007/s40273-017-0572-7.

23.

Early health technology assessment of magnetic resonance-guided high intensity focused ultrasound ablation for the treatment of early-stage breast cancer.

Knuttel FM, Huijsse SEM, Feenstra TL, Moonen CTW, van den Bosch MAAJ, Buskens E, Greuter MJW, de Bock GH.

J Ther Ultrasound. 2017 Aug 1;5:23. doi: 10.1186/s40349-017-0101-3. eCollection 2017.

24.

The relationship between diabetes, diabetes-related complications and productive activities among older Europeans.

Rodriguez-Sanchez B, Alessie RJM, Feenstra TL, Angelini V.

Eur J Health Econ. 2018 Jun;19(5):719-734. doi: 10.1007/s10198-017-0911-9. Epub 2017 Jun 27.

25.

External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.

Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Hansen RN, Leidl R, Risebrough N, Samyshkin Y, Wacker M, Rutten-van Mölken MP.

Value Health. 2017 Mar;20(3):397-403. doi: 10.1016/j.jval.2016.10.016. Epub 2017 Jan 3.

26.

[Costs and benefits of smoking].

Polder JJ, van Gils PF, Kok L, Talhout R, Feenstra TL.

Ned Tijdschr Geneeskd. 2017;160:D833. Dutch.

PMID:
28181894
27.

Adhesion of Escherichia coli under flow conditions reveals potential novel effects of FimH mutations.

Feenstra T, Thøgersen MS, Wieser E, Peschel A, Ball MJ, Brandes R, Satchell SC, Stockner T, Aarestrup FM, Rees AJ, Kain R.

Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):467-478. doi: 10.1007/s10096-016-2820-8. Epub 2016 Nov 5.

28.

Diabetes-Associated Factors as Predictors of Nursing Home Admission and Costs in the Elderly Across Europe.

Rodríguez-Sánchez B, Angelini V, Feenstra T, Alessie RJ.

J Am Med Dir Assoc. 2017 Jan;18(1):74-82. doi: 10.1016/j.jamda.2016.09.011. Epub 2016 Nov 1.

PMID:
27815109
29.

Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?

Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Borg S, Dal Negro RW, Hansen RN, Jansson SA, Leidl R, Risebrough N, Samyshkin Y, Wacker ME, Rutten-van Mölken MPMH.

Value Health. 2016 Sep - Oct;19(6):800-810. doi: 10.1016/j.jval.2016.04.002. Epub 2016 May 21.

30.

Projecting the COPD population and costs in England and Scotland: 2011 to 2030.

McLean S, Hoogendoorn M, Hoogenveen RT, Feenstra TL, Wild S, Simpson CR, Mölken MR, Sheikh A.

Sci Rep. 2016 Sep 1;6:31893. doi: 10.1038/srep31893.

31.

Individual patient information to select patients for different radiation techniques.

Quik EH, Feenstra TL, Postmus D, Slotman BJ, Leemans CR, Krabbe PF, Langendijk JA.

Eur J Cancer. 2016 Jul;62:18-27. doi: 10.1016/j.ejca.2016.04.008. Epub 2016 May 10.

PMID:
27185574
32.

Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.

de Boer PT, Frederix GW, Feenstra TL, Vemer P.

Pharmacoeconomics. 2016 Sep;34(9):833-45. doi: 10.1007/s40273-016-0410-3. Review.

33.

Cost-effectiveness of implant-supported mandibular removable partial dentures.

Jensen C, Ross J, Feenstra TL, Raghoebar GM, Speksnijder C, Meijer HJA, Cune MS.

Clin Oral Implants Res. 2017 May;28(5):594-601. doi: 10.1111/clr.12840. Epub 2016 Apr 14.

PMID:
27080041
34.

Correspondence - Reply to THEBREAST-D-15-702.

Koleva-Kolarova RG, Zhan Z, Greuter MJ, Feenstra TL, De Bock GH.

Breast. 2016 Jun;27:184-5. doi: 10.1016/j.breast.2016.03.001. Epub 2016 Apr 4. No abstract available.

PMID:
27056287
35.

AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users.

Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL.

Pharmacoeconomics. 2016 Apr;34(4):349-61. doi: 10.1007/s40273-015-0327-2.

36.

Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas.

Zhang L, Kundu S, Feenstra T, Li X, Jin C, Laaniste L, El Hassan TE, Ohlin KE, Yu D, Olofsson T, Olsson AK, Pontén F, Magnusson PU, Nilsson KF, Essand M, Smits A, Dieterich LC, Dimberg A.

Sci Signal. 2015 Dec 8;8(406):ra125. doi: 10.1126/scisignal.aaa1690.

PMID:
26645582
37.

To screen or not to screen for breast cancer? How do modelling studies answer the question?

Koleva-Kolarova RG, Zhan Z, Greuter MJ, Feenstra TL, De Bock GH.

Curr Oncol. 2015 Oct;22(5):e380-2. doi: 10.3747/co.22.2889.

38.

Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives.

Bindels J, Ramaekers B, Ramos IC, Mohseninejad L, Knies S, Grutters J, Postma M, Al M, Feenstra T, Joore M.

Pharmacoeconomics. 2016 Mar;34(3):315-22. doi: 10.1007/s40273-015-0346-z.

39.

Operational Validation of Health Economic Decision Analytic Models.

Corro Ramos I, Al MJ, Vemer P, Feenstra TF, van Voorn G.

Value Health. 2015 Nov;18(7):A706. doi: 10.1016/j.jval.2015.09.2649. Epub 2015 Oct 20. No abstract available.

40.

Assessment of Validation of Health-Economics Decision Models In Intervention Studies of Seasonal Influenza and Breast Cancer.

de Boer PT, Frederix GW, Al MJ, Feenstra TF, Vemer P.

Value Health. 2015 Nov;18(7):A704. doi: 10.1016/j.jval.2015.09.2637. Epub 2015 Oct 20. No abstract available.

41.

Patient Heterogeneity In Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (Copd): are Current Models Suitable to Evaluate Personalized Medicine.

Hoogendoorn M, Feenstra T, Asukai Y, Briggs A, Borg S, Dal Negro R, Hansen RN, Jansson S, Wacker M, Risebrough N, Samyshkin Y, Leidl R, Rutten van-Mölken M.

Value Health. 2015 Nov;18(7):A694. doi: 10.1016/j.jval.2015.09.2586. Epub 2015 Oct 20. No abstract available.

42.

The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling.

van Voorn GA, Vemer P, Hamerlijnck D, Ramos IC, Teunissen GJ, Al M, Feenstra TL.

Appl Health Econ Health Policy. 2016 Apr;14(2):129-33. doi: 10.1007/s40258-015-0200-7.

43.

Cost effectiveness and budgetary impact of the Boston University approach to Psychiatric Rehabilitation for societal participation in people with severe mental illness: a randomised controlled trial protocol.

Sanches SA, Swildens WE, van Busschbach JT, Stant AD, Feenstra TL, van Weeghel J.

BMC Psychiatry. 2015 Sep 15;15:217. doi: 10.1186/s12888-015-0593-8.

44.

Continuous-Time Semi-Markov Models in Health Economic Decision Making: An Illustrative Example in Heart Failure Disease Management.

Cao Q, Buskens E, Feenstra T, Jaarsma T, Hillege H, Postmus D.

Med Decis Making. 2016 Jan;36(1):59-71. doi: 10.1177/0272989X15593080. Epub 2015 Jul 14.

45.

Policy evaluation in diabetes prevention and treatment using a population-based macro simulation model: the MICADO model.

van der Heijden AA, Feenstra TL, Hoogenveen RT, Niessen LW, de Bruijne MC, Dekker JM, Baan CA, Nijpels G.

Diabet Med. 2015 Dec;32(12):1580-7. doi: 10.1111/dme.12811. Epub 2015 Jun 15.

PMID:
26010494
46.

Simulation models in population breast cancer screening: A systematic review.

Koleva-Kolarova RG, Zhan Z, Greuter MJ, Feenstra TL, De Bock GH.

Breast. 2015 Aug;24(4):354-63. doi: 10.1016/j.breast.2015.03.013. Epub 2015 Apr 21. Review.

PMID:
25906671
47.

The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.

Koleva-Kolarova RG, Greuter MJ, van Kruchten M, Vermeulen KM, Feenstra T, Buskens E, Glaudemans AW, de Vries EF, de Vries EG, Hospers GA, de Bock GH.

Br J Cancer. 2015 May 12;112(10):1617-25. doi: 10.1038/bjc.2015.138. Epub 2015 Apr 16.

48.

Evaluation of patient registries supporting reimbursement decisions: the case of oxaliplatin for treatment of stage III colon cancer.

Mohseninejad L, van Gils C, Uyl-de Groot CA, Buskens E, Feenstra T.

Value Health. 2015 Jan;18(1):84-90. doi: 10.1016/j.jval.2014.10.008.

49.

Dealing With Missing Behavioral Endpoints in Health Promotion Research by Modeling Cognitive Parameters in Cost-Effectiveness Analyses of Behavioral Interventions: A Validation Study.

Prenger R, Pieterse ME, Braakman-Jansen LM, Feenstra TL, Smit ES, Hoving C, de Vries H, van Ommeren JK, Evers SM, van der Palen J.

Health Econ. 2016 Jan;25(1):24-39. doi: 10.1002/hec.3119. Epub 2014 Dec 1.

PMID:
25448460
50.

Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (COPD): Cross-Model Comparison of Hypothetical Treatment Scenarios.

Hoogendoorn M, Feenstra T, Asukai Y, Borg S, Hansen RN, Jansson SA, Samyshkin Y, Wacker M, Briggs A, Lloyd A, Sullivan SD, Rutten-van Mölken MP.

Value Health. 2014 Nov;17(7):A557-8. doi: 10.1016/j.jval.2014.08.1836. Epub 2014 Oct 26. No abstract available.

Supplemental Content

Loading ...
Support Center